Explore the vast range of titles available.

Autonomous laboratories can accelerate discoveries in chemical synthesis, but this requires automated measurements coupled with reliable decision-making 1 , 2 . Most autonomous laboratories involve bespoke automated equipment 3 – 6 , and reaction outcomes are often assessed using a single, hard-wired characterization technique 7 . Any decision-making algorithms 8 must then operate using this narrow range of characterization data 9 , 10 . By contrast, manual experiments tend to draw on a wider range of instruments to characterize reaction products, and decisions are rarely taken based on one measurement alone. Here we show that a synthesis laboratory can be integrated into an autonomous laboratory by using mobile robots 11 – 13 that operate equipment and make decisions in a human-like way. Our modular workflow combines mobile robots, an automated synthesis platform, a liquid chromatography–mass spectrometer and a benchtop nuclear magnetic resonance spectrometer. This allows robots to share existing laboratory equipment with human researchers without monopolizing it or requiring extensive redesign. A heuristic decision-maker processes the orthogonal measurement data, selecting successful reactions to take forward and automatically checking the reproducibility of any screening hits. We exemplify this approach in the three areas of structural diversification chemistry, supramolecular host–guest chemistry and photochemical synthesis. This strategy is particularly suited to exploratory chemistry that can yield multiple potential products, as for supramolecular assemblies, where we also extend the method to an autonomous function assay by evaluating host–guest binding properties. A modular autonomous platform for general exploratory synthetic chemistry uses mobile robots to integrate an automated synthesis platform and two analysis platforms.

Small-molecule synthesis usually relies on procedures that are highly customized for each target. A broadly applicable automated process could greatly increase the accessibility of this class of compounds to enable investigations of their practical potential. Here we report the synthesis of 14 distinct classes of small molecules using the same fully automated process. This was achieved by strategically expanding the scope of a building block–based synthesis platform to include even Csp3-rich polycyclic natural product frameworks and discovering a catch-and-release chromatographic purification protocol applicable to all of the corresponding intermediates. With thousands of compatible building blocks already commercially available, many small molecules are now accessible with this platform. More broadly, these findings illuminate an actionable roadmap to a more general and automated approach for small-molecule synthesis.

Automated synthesis platforms accelerate and simplify the preparation of molecules by removing the physical barriers to organic synthesis. This provides unrestricted access to biopolymers and small molecules via reproducible and directly comparable chemical processes. Current automated multistep syntheses rely on either iterative 1 – 4 or linear processes 5 – 9 , and require compromises in terms of versatility and the use of equipment. Here we report an approach towards the automated synthesis of small molecules, based on a series of continuous flow modules that are radially arranged around a central switching station. Using this approach, concise volumes can be exposed to any reaction conditions required for a desired transformation. Sequential, non-simultaneous reactions can be combined to perform multistep processes, enabling the use of variable flow rates, reuse of reactors under different conditions, and the storage of intermediates. This fully automated instrument is capable of both linear and convergent syntheses and does not require manual reconfiguration between different processes. The capabilities of this approach are demonstrated by performing optimizations and multistep syntheses of targets, varying concentrations via inline dilutions, exploring several strategies for the multistep synthesis of the anticonvulsant drug rufinamide 10 , synthesizing eighteen compounds of two derivative libraries that are prepared using different reaction pathways and chemistries, and using the same reagents to perform metallaphotoredox carbon–nitrogen cross-couplings 11 in a photochemical module—all without instrument reconfiguration. An automated synthesis instrument comprising a series of continuous flow modules that are radially arranged around a central switching station can achieve both linear and convergent syntheses.

Three-dimensional (3D) printing has the potential to transform science and technology by creating bespoke, low-cost appliances that previously required dedicated facilities to make. An attractive, but unexplored, application is to use a 3D printer to initiate chemical reactions by printing the reagents directly into a 3D reactionware matrix, and so put reactionware design, construction and operation under digital control. Here, using a low-cost 3D printer and open-source design software we produced reactionware for organic and inorganic synthesis, which included printed-in catalysts and other architectures with printed-in components for electrochemical and spectroscopic analysis. This enabled reactions to be monitored in situ so that different reactionware architectures could be screened for their efficacy for a given process, with a digital feedback mechanism for device optimization. Furthermore, solely by modifying reactionware architecture, reaction outcomes can be altered. Taken together, this approach constitutes a relatively cheap, automated and reconfigurable chemical discovery platform that makes techniques from chemical engineering accessible to typical synthetic laboratories. A low-cost 3D printer is used to combine chemical reactions and the reactor to produce an active ‘reactionware’ system for organic and inorganic synthesis. Active elements such as catalysts can be incorporated into the walls of printed reactors, and other printed-in components that enable electrochemical and spectroscopic analysis can also be included.

Metal-organic frameworks (MOFs) are porous, crystalline materials with well-defined structures that can be used in many applications, from gas storage to catalysis and drug storage. This protocol is for the preparation of the MOF NU-1000. The synthesis of NU-1000, a highly robust mesoporous (containing pores >2 nm) metal-organic framework (MOF), can be conducted efficiently on a multigram scale from inexpensive starting materials. Tetrabromopyrene and (4-(ethoxycarbonyl)phenyl)boronic acid can easily be coupled to prepare the requisite organic strut with four metal-binding sites in the form of four carboxylic acids, while zirconyl chloride octahydrate is used as a precursor for the well-defined metal oxide clusters. NU-1000 has been reported as an excellent candidate for the separation of gases, and it is a versatile scaffold for heterogeneous catalysis. In particular, it is ideal for the catalytic deactivation of nerve agents, and it shows great promise as a new generic platform for a wide range of applications. Multiple post-synthetic modification protocols have been developed using NU-1000 as the parent material, making it a potentially useful scaffold for several catalytic applications. The procedure for the preparation of NU-1000 can be scaled up reliably, and it is suitable for the production of 50 g of the tetracarboxylic acid containing organic linker and 200 mg–2.5 g of NU-1000. The entire synthesis is performed without purification by column chromatography and can be completed within 10 d.

A new class of chemical instrumentation seeks to alleviate the tedium and complexity of organic syntheses. A new class of chemical instrumentation seeks to alleviate the tedium and complexity of organic syntheses. Close up view of dials and wires on Marty Burke’s synthesis machine which assembles complex molecules robotically.

The infrastructure for chemical synthesis typically lies at either end of a spectrum: small-scale studies in ad hoc assemblies of glassware or large-scale production in capital-intensive custom reactors. Kitson et al. report a hybrid protocol that customizes a blueprint for synthesis of a target compound in a series of interconnected plastic modules, which can be assembled en masse by 3D printing (see the Perspective by Hornung). The approach, demonstrated for the commercial muscle relaxant baclofen, establishes a systematic workflow that is potentially amenable to automation: All that is necessary for synthesis and purification is the introduction of stock solutions and variation of temperature or pressure. Science , this issue p. 314 ; see also p. 273 A blueprint for chemical synthesis in plasticware offers an alternative to capital-intensive reactors for low-volume targets. Chemical manufacturing is often done at large facilities that require a sizable capital investment and then produce key compounds for a finite period. We present an approach to the manufacturing of fine chemicals and pharmaceuticals in a self-contained plastic reactionware device. The device was designed and constructed by using a chemical to computer-automated design (ChemCAD) approach that enables the translation of traditional bench-scale synthesis into a platform-independent digital code. This in turn guides production of a three-dimensional printed device that encloses the entire synthetic route internally via simple operations. We demonstrate the approach for the γ-aminobutyric acid receptor agonist, (±)-baclofen, establishing a concept that paves the way for the local manufacture of drugs outside of specialist facilities.

This Protocol covers the synthesis of NaGdF 4 nanoparticles that incorporate lanthanide ions in different layers and can be used as luminescent probes that efficiently convert near-infrared excitation wavelengths into tunable visible emissions. Sodium gadolinium fluoride (NaGdF 4 ) is an ideal host material for the incorporation of luminescent lanthanide ions because of its high photochemical stability, low vibrational energy and its ability to mediate energy exchanges between the lanthanide dopants. This protocol describes the detailed experimental procedure for synthesizing core-shell NaGdF 4 nanoparticles that incorporate lanthanide ions into different layers for efficiently converting a single-wavelength, near-IR excitation into a tunable visible emission. These nanoparticles can then be used as luminescent probes in biological samples, in 3D displays, in solar energy conversion and in photodynamic therapy. The NaGdF 4 nanoparticles are grown through co-precipitation in a binary solvent mixture of oleic acid and 1-octadecene. Doping by lanthanides with controlled compositions and concentrations can be achieved concomitantly with particle growth. The lanthanide-doped NaGdF 4 nanoparticles then serve as seed crystals for subsequent epitaxial growth of shell layers comprising different lanthanide dopants. The entire procedure for the preparation and isolation of the core-shell nanoparticles comprising two epitaxial shell layers requires ∼15 h for completion.

Flow chemistry is an attractive alternative to batch chemistry in cases in which improved safety and reaction efficiency can be achieved. This protocol describes the assembly of a continuous flow apparatus from readily available and affordable parts. The adoption of and opportunities in continuous flow synthesis ('flow chemistry') have increased significantly over the past several years. Continuous flow systems provide improved reaction safety and accelerated reaction kinetics, and have synthesised several active pharmaceutical ingredients in automated reconfigurable systems. Although continuous flow platforms are commercially available, systems constructed 'in-lab' provide researchers with a flexible, versatile, and cost-effective alternative. Herein, we describe the assembly and use of a modular continuous flow apparatus from readily available and affordable parts in as little as 30 min. Once assembled, the synthesis of a sulfonamide by reacting 4-chlorobenzenesulfonyl chloride with dibenzylamine in a single reactor coil with an in-line quench is presented. This example reaction offers the opportunity to learn several important skills including reactor construction, charging of a back-pressure regulator, assembly of stainless-steel syringes, assembly of a continuous flow system with multiple junctions, and yield determination. From our extensive experience of single-step and multistep continuous flow synthesis, we also describe solutions to commonly encountered technical problems such as precipitation of solids ('clogging') and reactor failure. Following this protocol, a nonspecialist can assemble a continuous flow system from reactor coils, syringes, pumps, in-line liquid–liquid separators, drying columns, back-pressure regulators, static mixers, and packed-bed reactors.

The continuous-flow synthesis of both enantiomers of a complex molecule, the anti-inflammatory drug rolipram, is described, using only columns packed with achiral and chiral heterogeneous catalysts, thus enabling batch processing to be avoided. Fine chemicals can grow with the flow The continuous flow manufacturing systems that are the norm for the production of heavy chemicals are not generally used in the production of more complex and delicate fine chemicals and pharmaceuticals, where 'batch' processes remain the preferred method. This paper proposes a protocol that may bring the efficiency, safety and other benefits of continuous flow to the synthesis of drug-like molecules. Using only columns packed with heterogeneous catalysts, the authors passed commercially available starting materials successively through four columns containing achiral and chiral heterogeneous catalysts to synthesize the GABA-related anti-inflammatory drugs ( R )-rolipram, ( S )-rolipram and ( R )-phenibut. The present multistep continuous flow synthesis runs at the laboratory scale, producing the drugs obtained on a gram scale; now work is under way to scale-up to multi-kilogram syntheses of drugs. Chemical manufacturing is conducted using either batch systems or continuous-flow systems. Flow systems have several advantages over batch systems, particularly in terms of productivity, heat and mixing efficiency, safety, and reproducibility 1 , 2 , 3 , 4 . However, for over half a century, pharmaceutical manufacturing has used batch systems because the synthesis of complex molecules such as drugs has been difficult to achieve with continuous-flow systems 5 , 6 . Here we describe the continuous-flow synthesis of drugs using only columns packed with heterogeneous catalysts. Commercially available starting materials were successively passed through four columns containing achiral and chiral heterogeneous catalysts to produce ( R )-rolipram 7 , an anti-inflammatory drug and one of the family of γ-aminobutyric acid (GABA) derivatives 8 . In addition, simply by replacing a column packed with a chiral heterogeneous catalyst with another column packed with the opposing enantiomer, we obtained antipole ( S )-rolipram. Similarly, we also synthesized ( R )-phenibut, another drug belonging to the GABA family. These flow systems are simple and stable with no leaching of metal catalysts. Our results demonstrate that multistep (eight steps in this case) chemical transformations for drug synthesis can proceed smoothly under flow conditions using only heterogeneous catalysts, without the isolation of any intermediates and without the separation of any catalysts, co-products, by-products, and excess reagents. We anticipate that such syntheses will be useful in pharmaceutical manufacturing.